Bionano Genomics price to sales ratio BNGO

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 0.4×
8-year median: 2.3×
Against its 8-year history: 11th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.1× to 199×
Peer median: 1.1×

Bionano Genomics' price to sales ratio is 0.4× as of Oct 23, 2026.

That is below its 8-year median of 2.3×, lower than on 89% of days in the last 8 years.

Over that time it ranged from 0.1× in Mar 2025 to 199× in Jun 2021.

The median for 7 healthcare stocks of a similar size is 1.1×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.4×	0.4×	0.7×
2025	0.5×	0.1×	1.0×
2024	0.6×	0.6×	2.0×
2023	2.2×	1.4×	21.4×
2022	16.7×	16.7×	50.2×
2021	55.2×	55.2×	199×
2020	64.6×	1.0×	64.6×
2019	2.5×	0.6×	4.2×

Against its peers

Companies in Healthcare nearest Bionano Genomics' size, closest first, today.

Company	Price to sales ratio
BNGOBionano Genomics	0.4×
NEPHNephros	1.9×
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
Peer median	1.1×

Where Bionano Genomics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Bionano Genomics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.